drugset

drugset / Trial / NCT00756041

Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy

NCT00756041 ↗

Phase 2 Terminated 221 enrolled Takeda

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety of TAK-128, once daily (QD), for treatment of diabetic peripheral neuropathy

Timeline

Start: 2005-09
Primary completion: 2006-09
Completion: 2006-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sapanisertib	Small molecule	100 mg	Oral

Indications